Our top pick for
Agilysys Inc is a software-application business based in the US. Agilysys shares (AGYS) are listed on the NASDAQ and all prices are listed in US Dollars. Agilysys employs 1,350 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$52.26|
|52-week range||$25.06 - $64.09|
|50-day moving average||$52.69|
|200-day moving average||$53.24|
|Wall St. target price||$62.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.87|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-1.75%|
|1 month (2021-09-24)||-0.72%|
|3 months (2021-07-26)||-7.73%|
|6 months (2021-04-26)||-0.53%|
|1 year (2020-10-26)||102.40%|
|2 years (2019-10-25)||104.14%|
|3 years (2018-10-26)||225.00%|
|5 years (2016-10-26)||438.21%|
Valuing Agilysys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agilysys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Agilysys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.2 million.
The EBITDA is a measure of a Agilysys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$146.1 million|
|Gross profit TTM||$89.4 million|
|Return on assets TTM||-5.71%|
|Return on equity TTM||-16.38%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
There are currently 471,693 Agilysys shares held short by investors – that's known as Agilysys's "short interest". This figure is 2.8% up from 458,734 last month.
There are a few different ways that this level of interest in shorting Agilysys shares can be evaluated.
Agilysys's "short interest ratio" (SIR) is the quantity of Agilysys shares currently shorted divided by the average quantity of Agilysys shares traded daily (recently around 86708.272058824). Agilysys's SIR currently stands at 5.44. In other words for every 100,000 Agilysys shares traded daily on the market, roughly 5440 shares are currently held short.
However Agilysys's short interest can also be evaluated against the total number of Agilysys shares, or, against the total number of tradable Agilysys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agilysys's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Agilysys shares in existence, roughly 20 shares are currently held short) or 0.0354% of the tradable shares (for every 100,000 tradable Agilysys shares, roughly 35 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agilysys.
Find out more about how you can short Agilysys stock.
We're not expecting Agilysys to pay a dividend over the next 12 months.
Agilysys's shares were split on a 3:2 basis on 6 September 1995. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Agilysys shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Agilysys shares which in turn could have impacted Agilysys's share price.
Over the last 12 months, Agilysys's shares have ranged in value from as little as $25.055 up to $64.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agilysys's is 1.4804. This would suggest that Agilysys's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agilysys, Inc. , together with its subsidiaries, operates as a developer and marketer of hardware and software products and services to the hospitality industry in North America, Europe, the Asia-Pacific, and India. It offers point of sale, property management systems, payment, inventory and procurement, reservations and venue management, activity management, document management, and analytics and marketing loyalty solutions to enhance guest experience. The company also provides technical software support, maintenance, and subscription services; and professional services. It offers its solutions for gaming, hotels, resorts and cruise, corporate foodservice management, restaurants, universities, stadia, and healthcare. The company was formerly known as Pioneer-Standard Electronics, Inc. and changed its name to Agilysys, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.